Literature DB >> 31643050

Transglutaminase-Mediated Conjugations.

Yasuaki Anami1, Kyoji Tsuchikama2.   

Abstract

Microbial transglutaminase (MTGase) catalyzes site-specific transpeptidation between a primary amine within linkers and the side chain of glutamine 295 within deglycosylated chimeric, humanized, and human IgG1s, affording homogeneous antibody-drug conjugates (ADCs). This method can be empowered by mutation of asparagine 297, insertion of a glutamine-containing peptide tag, and the use of branched linkers. Such modifications facilitate the conjugation process and provide flexibility in adjusting the conjugation site and drug-to-antibody ratio (DAR). Here, we present a protocol optimized in our group for MTGase-mediated linker incorporation and subsequent click chemistry-based payload installation. Both small linear linkers and bulky branched linkers can be incorporated into the Fc moiety within various antibodies, affording homogeneous ADCs with defined DARs. Thanks to the high homogeneity, ADCs constructed using this method can be analyzed using a single-quadrupole electrospray ionization (ESI) mass spectrometer, which many laboratories own for regular analysis of small molecules and peptides. The approach presented here allows for facile and cost-effective production of various homogeneous ADCs and other antibody conjugates for research and clinical purposes.

Entities:  

Keywords:  Antibodies; Antibody–drug conjugates; Cancer; Chemotherapy; Conjugation; Homogeneous; Linker; Payload; Site-specific; Transglutaminase

Mesh:

Substances:

Year:  2020        PMID: 31643050     DOI: 10.1007/978-1-4939-9929-3_5

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.

Authors:  Summer Y Y Ha; Yasuaki Anami; Chisato M Yamazaki; Wei Xiong; Candice M Haase; Scott D Olson; Jangsoon Lee; Naoto T Ueno; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

Review 2.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.

Authors:  Yasuaki Anami; Yoshihiro Otani; Wei Xiong; Summer Y Y Ha; Aiko Yamaguchi; Kimberly A Rivera-Caraballo; Ningyan Zhang; Zhiqiang An; Balveen Kaur; Kyoji Tsuchikama
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

4.  Propofol Suppresses Microglia Inflammation by Targeting TGM2/NF-κB Signaling.

Authors:  Yuanyuan Hou; Xi Xiao; Wei Yu; Sihua Qi
Journal:  J Immunol Res       Date:  2021-08-24       Impact factor: 4.818

Review 5.  Novel development strategies and challenges for anti-Her2 antibody-drug conjugates.

Authors:  Xinling Zhang; Andrew C Huang; Fahai Chen; Hu Chen; Lele Li; Nana Kong; Wenting Luo; Jianmin Fang
Journal:  Antib Ther       Date:  2022-01-27

6.  Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance.

Authors:  Chisato M Yamazaki; Aiko Yamaguchi; Yasuaki Anami; Wei Xiong; Yoshihiro Otani; Jangsoon Lee; Naoto T Ueno; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

7.  LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.

Authors:  Yasuaki Anami; Mi Deng; Xun Gui; Aiko Yamaguchi; Chisato M Yamazaki; Ningyan Zhang; Cheng Cheng Zhang; Zhiqiang An; Kyoji Tsuchikama
Journal:  Mol Cancer Ther       Date:  2020-09-02       Impact factor: 6.261

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.